• darkblurbg

    Developing therapies

    for type 1 diabetes

  • darkblurbg

    Intralymphatic immunotherapy

    with Diamyd®

Regulatory Affairs Officer

We welcome candidates with relevant life science experience to join our team.

Calendar

 Dates for financial information and other events
September 1 − September 4, 2020
LSX Nordic Congress
October 7, 2020
Year-End Report
Year-End Report 2019/2020
November 5, 2020
Annual Report
Annual Report 2019/2020
November 26, 2020
Annual General Meeting
Annual General Meeting 2019/2020

Company Presentation

The topline results from DIAGNODE-2 will comprise both the primary clinical endpoint and the most important secondary clinical endpoints, as well as the results for the genetically defined subgroups. These results will have an impact on the final design of any upcoming late stage development trials, including the patient population that we will target for the drug label.

Ulf Hannelius
President and CEO, Diamyd Medical AB

THE COMPANY

Diamyd Medical is a Swedish clinical-stage diabetes company active in the field of pharmaceutical development
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)


Read More
  • Diabetes

    10-20% of the more than 400 million living with diabetes suffer from the autoimmune form of the disease, where the immune system destroys the insulin-producing cells. Preserving the insulin producing ability may decrease the risk of complications among patients with autoimmune diabetes by 60-80 percent.

  • Products

    The antigen-specific immunotherapy Diamyd® and the regenerative and immunomodulatory therapy Remygen® are two novel disease-modifying drugs in clinical development phase, aiming to preserve and regenerate the patients’ own insulin production.

  • Clinical Trials

    The efficacy of intralymphatic administration of Diamyd® on preserving the insulin producing ability in type 1 diabetes is being confirmed in the Phase IIb trial DIAGNODE-2. The safety and efficacy of Remygen® on stimulating growth of insulin producing cells in type 1 diabetes is being evaluated for the first time in the Phase I/II trial ReGenerate-1.

Order GAD for preclinical research

GAD PRODUCTS